DAFTAR PUSTAKA

Alkhatieb, M., Mortada, H., & Aljaaly, H. 2020. Management of a Difficult-to-Treat Diabetic Foot Wound Complicated by Osteomyelitis: A Case Study. *Hindawi.* 7: 1-7. https://doi.org/ 10.1155/2020/3971581.

Alvarez, L.A., Sjipe, G.V.D., Desmet, S., Metsemakers, W.J., Spriet, I., Allegaert, K., & Rozenski, J. 2022. Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice. *Antibiotics*. 11 (701): 1–24. https://doi.org/10.3390/antibiotics11050701.

Atlaw, A., Kebede, H. B. Abdela, A. A. & Woldeamanuel, Y. 2022. Bacterial isolates from diabetic foot ulcers and their antimicrobial resistance Profile from Selected Hospitals in Addis Ababa, Ethiopia. *Frontiers in Endocrinology.* 13: 1-10. Front. https://doi.org/10.3389/fendo.2022.987487.

Cano, A., Ettcheto, M., Espina, M., Lopez-Machado, A., Cajal, Y., Rabanal, F., Sancez-Lopez, E., Camins, A., Garcia, M. L., & Souto, E. B. State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. *Journal of Nanobiotechnology.*18 (156): 1-24https://doi.org/10.1186/s12951-020-00714-2.

Christen, M.O., dan Franco, V. 2020. Polycaprolactone: How a Well-Known and Futuristic Polymer Has Become an Innovative Collagen-Stimulator in Esthetics. *Clinical, Cosmetic and Investigational Dermatology*. 13: 31-48. https://doi.org/10.2147/CCID.S229054.

Hasan, N., Cao, J., Lee, J., Hlaing, S.P., Oshi, M.A., Naeem, M., Ki, M., Lee, B.L., Jung, Y., & Yoo, J. 2019. Bacteria-Targeted Clindamycin Loaded Polymeric Nanoparticles: Effect of Surface Charge on Nanoparticle Adhesion to MRSA, Antibacterial Activity, and Wound Healing. *Pharmaceutics*. 11 (239): 1-17. https://doi.org/10.3390/pharmaceutics11050236.

Hashmi, M. Z. 2020. *Antibiotics and Antimicrobial Resistance Genes, Emerging Contaminants and Associated Treatment Technologies*. Switzerland: Springer Nature Switzerland AG

Hung, S. Y., Chiu, C. H., Huang, C. H., Lin, C. W., Yeh, J. T., Yang, H. M., & Huang, Y. Y. 2022. Impact of Wound Microbiology on Limb Preservation in Patients with Diabetic Foot Infection. *Journal Diabetes Investigation*. 13 (2): 336-343. https://doi.org/10.1111/jdi.13649.

International Diabetes Federation. 2021. Five Question on the IDF Diabetes Atlas: *Diabetes Research and Clinical Practice*.

Joseph, M.K., Islam, M., Reineke, J., Hildreth, M., Woyengo, T., Pillatzki, A., Baride, A., dan Perumal, O., 2020. Intraductal Drug Delivery to the Breast: Effect of Particle Size and Formulation on Breast Duct and Lymph Node Retention. *Molecular Pharmaceutics*. 17: 441–452. https://doi.org/10.1021/acs.molpharmaceut.9b00879.

Kumar, A., Gangwar, R., Zargar, A. A., Kumar, R., & Sharma, A. 2023. *Prevalence of diabetes in India: A review of IDF Diabetes Atlas 10th edition*. Sharjah: Bentham Science Publishers.

Lavoie, H. M. M., Ramsey, A., Nguyen, M., & Singh, S. 2023. *Diabetic Foot Infection.* Treasure Island: Stat Pearls Publishing.

Lv, Y., Haiseng, H., Qi, J., Lu, Yi., Zhao, W., Dong, X., & Wu, W.2018. Visual validation of the measurement of entrapment efficiency of drug nanocarriers. *International Journal of Pharmaceutics*. 547 (1-2): 395-403. https://doi.org/10.1016/j.ijpharm.2018.06.025.

Macdonald, K.E., Boeckh, S., Stacey, H.J., & Jones, J.D. 2021. The Microbiology of Diabetic Foot Infections: A Meta-Analysis. *BMC Infectious Diseases*. 21 (770): 1–10. https://doi.org/10.1186/s12879-021-06516-7.

Mudjahid, M. Nainu, F., Utami, R.N., Sam, A., Marzaman, A.N.F., Roska, T.P., Asri, R.M., Himawan, A., Donelly, R.F., & Permana, A.D. 2022. Enhancement in Site-Specific Delivery of Chloramphenicol Using Bacterially Sensitive Microparticle Loaded into Dissolving Microneedle: Potential for Enhanced Effectiveness Treatment of Cellulitis. *ACS Appl. Mater. Interfaces*. 14 (51): 56560–56577. https://doi.org/10.1021/acsami.2c16857.

Murphy, P. B., Bistas, K. G., & Le, J. K. 2022. *Clindamycin*. Treasure Island: Stat Pearls Publishing.

Nather, A. 2023. *Understanding Diabetic Foot: A Comprehensive Guide For General Practitioners.* Hackensack : World Scientific Publishing Co.

Pavlovic, M., Bogicevic, I.A., Zaklan, D., Danic, M., Golocorbin-Kon, S., AlSalami, H., & Micov, N. 2022. Influence of Bile Acids in Hydrogel Pharmaceutical Formulations on Dissolution Rate and Permeation of Clindamycin Hydrochloride. *Gels*. 8 (35) :1-13. https://doi.org/10.3390/gels8010035.

Permana, A.D., Anjani, Q.K., Sartini, Utomo, E., Volpe-Zanutto, F., Paredes, A.J., Evary, Y.M., Mardikasari, S.A., Pratama, M.R., Tuany, I.N., dan Donnelly, R.F. 2021. Selective delivery of silver nanoparticles for improved treatment of biofilm skin infection using bacteria-responsive microparticles loaded into dissolving microneedles. *Materials Science and Engineering C.* 120: 1-16. https://doi.org/10.1016/j.msec.2020.111786.

Prajapati, P. K., Aggarwal, D., Upadhyay. S. K., Tuli, H. S., Yadav, M., & Sharma, A. K. 2020. Prevalence of Inducible Clindamycin Resistance in Methicillin Resistant Staphylococcus aureus Isolated from Different Clinical Samples Received in a Tertiary Care Hospital. *Bulletin of Pure and Applied Sciences.* 39A (2): 344-353. https://doi.org/10.5958/2320-3188.2020.00038.8.

Punnel, L.C., & Lunter, D.J. 2021. Film-Forming Systems for Dermal Drug Delivery. *Pharmaceutics*. 13 (932): 1-19. https://doi.org/10.3390/pharmaceutics13070932.

Raja, P. B., Munusamy, K. R., Perumal, V., & Ibrahim, M. N. M. 2022. Characterization of nanomaterial used in nanobioremediation. *Nano-Bioremediation : Fundamentals and Applications*. 57-83. https://doi.org/10.1016/B978-0-12-823962-9.00037-4.

Senneville, E., Albalawi, Z., van Asten, S. A., Abbas, Z. G., Allison, G., Aragon-Sanchez, J., Embil, J. M., Lavery, L. A., Alhasan, M., Oz, O., Uckay, I., Urbancic-Rovan, V., Xu, Z.-R., Peters, E. J. G., & International Working

Group on The Diabetic Foot. 2023. *Guidelines on the diagnosis and treatment of foot infection in persons with diabetes IWGDF / IDSA 2023.*

Shahab, M.S., Rizwanullah, M., Alshehri, S., dan Imam, S.S. 2020. Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: *In vitro*, ex vivo and toxicity assessments. *International Journal of Biological Macromolecules*. 163: 2392–2404. https://doi.org/10.1016/j.ijbiomac.2020.09.185

Silva, R. Y. P., Menezes, D. L. B., Oliveira, V. S., Converti, A., & Lima, Á. A. N. 2023. Microparticles in the Development and Improvement of Pharmaceutical Formulations: An Analysis of *In vitro* and In Vivo Studies. *International Journal of Molecular Science*. 24: 5441. https://doi.org/10.3390/ ijms24065441.

Sorber, R., & Abularrage, C.J. 2021. Diabetic Foot Ulcers: Epidemiology and the Role of Multidisciplinary Care Teams. *Seminars in Vascular Surgery*. 34 (2021): 47 -53. https://doi.org/10.1053/j.semvascsurg.2021.02.006.

Spížek, J., & Řezanka, T. 2017. Lincosamides: Chemical structure, biosynthesis, mechanism of action, resistance, and applications. *Biochemical Pharmacology.* 113: 20-28. https://doi.org/10.1016/j.bcp.2016.12.001.

Syafika, N., Azis, S.B.A., Enggi, C.K., Qonita, H.A., Mahmud, T.R.A., Abizart, A., Asri, R.M., dan Permana, A.D. 2023. Glucose-Responsive Microparticle-Loaded Dissolving Microneedles for Selective Delivery of Metformin: A Proof-of-Concept Study. *Molecular Pharmaceutics*. 20(2): 1269–1284. https://doi.org/10.1021/acs.molpharmaceut.2c00936.

Vlachopoulos, A., Karlioti, G., Balla, E., Daniilidis, V., Kalamas, T., Stefanidou, M., Bikiaris, N. D., Christodoulou, E., Koumentakou, I., Karavas, E. *et al*. 2022. Poly(Lactic Acid)-Based Microparticles for Drug Delivery Applications: An Overview of Recent Advances. *Pharmaceutics*. 14: 359. https://doi.org/10.3390/ pharmaceutics14020359.

LAMPIRAN

Lampiran 1. Skema kerja penelitian



Lampiran 2. Penentuan panjang gelombang dan kurva baku



a b

Gambar 11. Kurva baku klindamisin dalam PBS 7,4 (A), media TSB (B)

Lampiran 3. Perhitungan

Lampiran 3.1 Efisiensi Penjerapan

- **Untuk F4 Replikasi 1**
  - Perhitungan kadar obat bebas dalam mg/40 mL

$$y = 0{,}0616x + 0{,}0214$$

$$x = \frac{(y-a)}{b} \times \frac{(\text{volume sampel x faktor pengenceran})}{\text{faktor konversi}}$$

$$x = \frac{(1{,}279-0{,}0214)}{0{,}0616} \times \frac{(40 \times 100)}{1000}$$

$$x = \frac{1{,}2576}{0{,}0616} \times 4$$

$$x = 81{,}66 \text{ mg/40mL}$$

  - Perhitungan efisiensi penjerapan

$$\%\ EP = \frac{\text{Total obat - Obat bebas}}{\text{Total obat}} \times 100\%$$

$$\%\ EP = \frac{100 \text{ mg} - 81{,}66}{100 \text{ mg}} \times 100\%$$

$$\%\ EP = \frac{18{,}34 \text{ mg}}{100 \text{ mg}} \times 100\%$$

$$\%\ EP = 18{,}34\%$$

Lampiran 3.2 *Drug Loading*

- **Untuk F4 Replikasi 1**
  - Perhitungan kadar obat yang terenkapsulasi dalam mg

$$y = 0{,}0616x + 0{,}0214$$

$$x = \frac{(y-a)}{b} \times \frac{1}{\text{faktor konversi}}$$

$$x = \frac{(0{,}915-0{,}0214)}{0{,}0616} \times \frac{1}{1000}$$

$$x = \frac{1{,}2576}{0{,}0616} \times 4$$

$$x = 0{,}0145 \text{ mg}$$

- Perhitungan *drug loading*

  % DL $= \frac{\text{Obat yang terenkapsulasi}}{\text{Berat total MP-KLI}} \times 100\%$

  % DL $= \frac{0{,}0145 \text{ mg}}{0{,}057 \text{ mg}} \times 100\%$

  % DL = 25,43%

Lampiran 3.3 Uji Pelepasan secara *In vitro* KLI pada media PBS

- **Untuk jam ke-0,5 Replikasi 1**
  - Persamaan: y = 0,0616x + 0,0214
  - Absorbansi KLI jam ke-0,5 replikasi 1: 0,293

    y = 0,0616x + 0,0214

    0,293 = 0,0616x + 0,0214

    x $= \frac{0{,}293\text{-}0{,}0214 \text{ mg}}{0{,}0616 \text{ mg}}$ x faktor koreksi

    x $= \frac{0{,}466\text{-}0{,}0214 \text{ mg}}{0{,}0616 \text{ mg}} \times 4$

    x = 4,409 x 4

    x = 17,63 µg/mL

  - Konsentrasi dalam 1 mL = 17,63 µg/mL
  - Konsentrasi dalam 100 mL = 17,63 µg/mL x 100 mL

    = 1763 µg/100 mL

    = 1,763 mg/100 mL
  - Jumlah obat yang terlepas = 1,763 mg/100 mL
  - % Pelepasan $= \frac{1{,}763 \text{ mg}}{10 \text{ mg}} \times 100\%$

    = 17,63%

Lampiran 4. Tabel Hasil Evaluasi

Tabel 4. 1. Kurva Baku KLI dalam PBS 7.4

Konsentrasi	y1	y2	y3	Rata-rata
16	1,123	0,907	1,011	1,013
8	0,562	0,438	0,501	0,500
4	0,294	0,222	0,264	0,260
2	0,151	0,163	0,167	0,160
1	0,072	0,104	0,091	0,088
0,5	0,033	0,047	0,057	0,045

Tabel 4. 2. Kurva Baku KLI dalam Media TSB

Konsentrasi	y1	y2	y3	Rata-rata
32	1,168	0,944	1,051	1,054
16	0,576	0,456	0,521	0,517
8	0,306	0,231	0,275	0,270
4	0,157	0,169	0,174	0,166
2	0,075	0,108	0,095	0,092
1	0,034	0,049	0,059	0,047

Tabel 4. 3. Uji Ukuran Partikel

Replikasi	Formula					
	F1	F2	F3	F4	F5	F6
1	0,42	0,9	1,34	2,87	3,5	5,09
2	0,45	0,98	1,52	3,03	3,78	4,65
3	0,41	1,06	1,43	2,71	4,06	5,53
Rata-rata	0,43	0,98	1,43	2,87	3,78	5,09
SD	0,03	0,08	0,09	0,16	0,28	0,44

Tabel 4. 4. Uji Efisiensi Penjerapan

Formula	Absorbansi	Kadar Obat (mg/40 mL)	EE (%)	Rata-rata	SD	RSD (%)
F1	1,279	81,66	18,34	18,34	1,43	7,79
	1,257	80,23	19,77			
	1,301	83,09	16,91			
F2	1,093	69,59	30,41	28,32	2,09	7,37
	1,125	71,68	28,32			
	1,157	73,77	26,23			
F3	1,066	67,86	32,14	35,43	3,29	9,28

	0,965	61,28	38,72			
	1,016	64,57	35,43			
	0,792	50,02	49,98			
F4	0,742	46,79	53,21	49,98	3,23	6,46
	0,841	53,25	46,75			
	0,708	44,59	55,41			
F5	0,775	48,91	51,09	51,09	4,32	8,45
	0,841	53,23	46,77			
	0,822	51,97	48,03			
F6	0,689	43,33	56,67	52,35	4,32	8,25
	0,755	47,65	52,35			

Tabel 4. 5. Uji *Drug Loading*

Formula	Absorbansi	Kadar Obat (mg/mL)	Bobot MP	DL (%)	Rata-rata	SD	RSD (%)
	0,916	0,015		25,43			
F1	0,974	0,015	0,057	27,08	25,43	1,65	6,49
	0,858	0,014		23,78			
	0,733	0,012		22,12			
F2	0,675	0,011	0,052	20,34	20,34	1,78	8,75
	0,618	0,010		18,56			
	0,541	0,008		16,81			
F3	0,636	0,010	0,050	19,89	18,35	1,54	8,39
	0,589	0,009		18,35			
	0,683	0,011		19,09			
F4	0,637	0,010	0,056	17,75	19,09	1,34	7,02
	0,730	0,012		20,43			
	0,522	0,008		15,1			
F5	0,569	0,009	0,054	16,53	16,53	1,43	8,65
	0,617	0,010		17,96			
	0,507	0,008		15,38			
F6	0,426	0,007	0,051	12,8	14,09	1,29	9,16
	0,467	0,007		14,09			

Tabel 4. 6. Uji Permeasi Secara *In vitro* pada media PBS

- **KLI**

Waktu (Jam)	Absorbansi	Konsentrasi (µg/ml)	1 ml (µg)	Faktor Dilusi	100 ml (mg)	Faktor Koreksi	CUR release (mg)	Rata-Rata (mg)	SD	Pelepasan (%)	Rata-rata (%)	SD
0,5	0,293	17,636	17,636	4	1,764	0,000	1,764	1,76	0,006	17,71	17,65	2,19
	0,295	17,766	17,766	4	1,777	0,000	1,777			17,65		
	0,292	17,571	17,571	4	1,757	0,000	1,757			17,58		
1	0,687	56,532	56,532	4	5,653	0,057	5,710	2,42	0,10	58,43	58,43	9,3
	0,694	59,714	59,714	4	5,971	0,060	6,031			66,73		
	0,691	58,545	58,545	4	5,855	0,059	5,913			50,13		
2	0,988	96,013	96,013	4	9,601	0,153	9,754	2,78	0,09	98,09	98,09	13,93
	0,994	102,506	102,506	4	10,251	0,162	10,413			84,16		
	0,991	109,000	109,000	4	10,900	0,168	11,068			112,02		

- **MP-KLI**

Waktu (Jam)	Absorbansi	Konsentrasi (µg/ml)	1 ml (µg)	Faktor Dilusi	100 ml (mg)	Faktor Koreksi	CUR release (mg)	Rata-rata (mg)	SD	Pelepasan (%)	Rata-rata (%)	SD
0,5	0,138	3,410	3,406	1	0,341	0,000	0,341	0,327	0,016	0,32	0,32	0,05
	0,136	3,305	3,305	1	0,330	0,000	0,330			0,37		
	0,132	3,102	3,102	1	0,310	0,000	0,310			0,27		
1	0,172	5,132	5,132	1	0,513	0,005	0,518	0,529	0,010	0,62	0,54	0,08
	0,174	5,234	5,234	1	0,523	0,005	0,529			0,54		
	0,176	5,335	5,335	1	0,534	0,005	0,539			0,46		

	0,248	8,992	8,992	1	0,899	0,014	0,913			1,12		
2	0,258	9,491	9,491	1	0,949	0,015	0,964	0,964	0,050	0,98	0,98	0,14
	0,268	9,990	9,990	1	0,999	0,015	1,014			0,84		
	0,307	11,985	11,985	1	1,199	0,026	1,225			1,4		
3	0,317	12,484	12,484	1	1,248	0,027	1,276	1,276	0,051	1,06	1,23	0,17
	0,327	12,983	12,983	1	1,298	0,028	1,327			1,23		
	0,351	14,230	14,230	1	1,423	0,040	1,463			2,39		
4	0,371	15,247	15,247	1	1,525	0,042	1,567	1,567	0,104	2,09	2,09	0,3
	0,391	16,264	16,264	1	1,626	0,045	1,671			1,79		
	0,411	17,281	17,281	1	1,728	0,058	1,786			2,45		
5	0,431	18,298	18,298	1	1,830	0,061	1,891	1,891	0,105	2,1	2,45	0,35
	0,451	19,315	19,315	1	1,932	0,064	1,995			2,8		
	0,471	20,332	20,332	1	2,033	0,078	2,111			2,65		
6	0,491	21,349	21,349	1	2,135	0,082	2,217	2,217	0,106	3,53	3,09	0,44
	0,512	22,366	22,366	1	2,237	0,086	2,323			3,09		
	0,532	23,383	23,383	1	2,338	0,101	2,440			9,26		
7	0,552	24,400	24,400	1	2,440	0,107	2,547	2,547	0,107	10,57	9,26	1,31
	0,572	25,418	25,418	1	2,542	0,112	2,653			7,95		
	0,592	26,435	26,435	1	2,643	0,128	2,771			10,98		
8	0,612	27,452	27,452	1	2,745	0,134	2,879	2,879	0,108	9,42	10,98	1,56
	0,632	28,469	28,469	1	2,847	0,140	2,987			12,54		
12	0,652	29,486	29,486	1	2,949	0,157	3,106	3,215	0,109	12,35	12,35	1,75
	0,672	30,503	30,503	1	3,050	0,164	3,215			14,1		

	0,692	31,520	31,520	1	3,152	0,172	3,324			10,6		
	0,712	32,537	32,537	1	3,254	0,160	3,414			18,89		
24	0,732	33,554	33,554	1	3,355	0,168	3,523	3,523	0,109	14,19	16,54	2,35
	0,752	34,571	34,571	1	3,457	0,175	3,632			16,54		

Tabel 4. 7. Uji Permeasi Secara *In vitro* pada media TSB

- **KLI**

Waktu (Jam)	Absorbansi	Konsentrasi (µg/ml)	1 ml (µg)	Faktor Dilusi	100 ml (mg)	Faktor Koreksi	CUR release (mg)	Rata-Rata (mg)	SD	Pelepasan (%)	Rata-rata (%)	SD
	0,432	18,330	18,330	4	1,833	0,000	1,83			17,65		
0,5	0,437	18,584	18,584	4	1,858	0,000	1,86	1,85	0,01	20,16		
	0,435	18,482	18,482	4	1,848	0,000	1,85			15,14	17,65	25,31
	0,714	32,645	32,645	4	3,264	0,033	3,30			68,12		
1	0,722	33,051	33,051	4	3,305	0,033	3,34	3,35	0,06	59,65		
	0,738	33,863	33,863	4	3,386	0,034	3,42			51,18	59,65	27,92
	0,996	46,959	46,959	4	4,696	0,080	4,78			113,76		
2	0,993	46,807	46,807	4	4,681	0,080	4,76	4,76	0,02	85,52		
	0,989	46,604	46,604	4	4,660	0,080	4,74			99,64	99,64	14,12

- **MP-KLI**

Waktu (Jam)	Absorbansi	Konsentrasi (µg/ml)	1 ml (µg)	Faktor DIlusi	100 ml (mg)	Faktor Koreksi	CUR release (mg)	Rata-Rata (mg)	SD	Pelepasan (%)	Rata-rata (%)	SD
0,5	0,159	4,457	4,457	1	0,446	0,000	0,446	0,430	0,018	0,25	0,29	0,04
	0,156	4,340	4,340	1	0,434	0,000	0,434			0,29		

	0,152	4,107	4,107	1	0,411	0,000	0,411			0,33		
	0,198	6,442	6,442	1	0,644	0,006	0,651			0,42		
1	0,200	6,558	6,558	1	0,656	0,007	0,662	0,662	0,012	0,49	0,49	0,07
	0,202	6,675	6,675	1	0,668	0,007	0,674			0,56		
	0,285	10,880	10,880	1	1,088	0,017	1,105			0,99		
2	0,297	11,454	11,454	1	1,145	0,018	1,163	1,163	0,058	0,87	0,87	0,12
	0,308	12,028	12,028	1	1,203	0,019	1,221			0,75		
	0,353	14,323	14,323	1	1,432	0,032	1,464			1,56		
3	0,364	14,897	14,897	1	1,490	0,033	1,523	1,523	0,059	1,82	1,82	0,26
	0,376	15,470	15,470	1	1,547	0,034	1,581			2,08		
	0,404	16,905	16,905	1	1,690	0,049	1,739			2,82		
4	0,427	18,074	18,074	1	1,807	0,051	1,858	1,858	0,119	3,22	2,82	0,4
	0,450	19,244	19,244	1	1,924	0,053	1,978			2,42		
	0,473	20,413	20,413	1	2,041	0,069	2,110			3,45		
5	0,496	21,583	21,583	1	2,158	0,073	2,231	2,231	0,121	3,02	3,02	0,43
	0,519	22,753	22,753	1	2,275	0,076	2,351			2,59		
	0,542	23,922	23,922	1	2,392	0,093	2,485			3,04		
6	0,565	25,092	25,092	1	2,509	0,098	2,607	2,607	0,122	3,54	3,54	0,5
	0,588	26,261	26,261	1	2,626	0,102	2,729			4,04		
	0,611	27,431	27,431	1	2,743	0,120	2,863			6,37		
7	0,634	28,600	28,600	1	2,860	0,126	2,986	2,986	0,123	7,42	7,42	1,05
	0,657	29,770	29,770	1	2,977	0,132	3,109			8,47		
8	0,680	30,940	30,940	1	3,094	0,151	3,245	3,369	0,124	9,09	9,09	1,29

	0,703	32,109	32,109	1	3,211	0,158	3,369			7,8		
	0,726	33,279	33,279	1	3,328	0,165	3,493			10,38		
	0,750	34,448	34,448	1	3,445	0,186	3,631			11,17		
12	0,773	35,618	35,618	1	3,562	0,194	3,756	3,756	0,125	14,87	13,02	1,85
	0,796	36,787	36,787	1	3,679	0,202	3,881			13,02		
	0,819	37,957	37,957	1	3,796	0,189	3,985			14,62		
24	0,842	39,127	39,127	1	3,913	0,197	4,110	4,110	0,125	17,04	17,03	2,41
	0,865	40,296	40,296	1	4,030	0,206	4,235			19,45		

Tabel 4. 8. Uji Permeasi Secara *In vitro* pada media TSB Kultur *S. aureus*

- **KLI**

Waktu (Jam)	Absorbansi	Konsentrasi (µg/ml)	1 ml (µg)	Faktor Dilusi	100 ml (mg)	Faktor Koreksi	CUR release (mg)	Rata-Rata (mg)	SD	Pelepasan (%)	Rata-rata (%)	SD
	0,442	18,838	18,838	1	1,884	0,000	1,88			17,22		
0,5	0,447	19,091	19,091	1	1,909	0,000	1,91	1,90	0,01	15,08		
	0,445	18,990	18,990	1	1,899	0,000	1,90			12,94	15,08	2,14
	0,725	33,203	33,203	1	3,320	0,033	3,35			69,76		
1	0,733	33,609	33,609	1	3,361	0,034	3,39	3,37	0,02	52,49		
	0,728	33,355	33,355	1	3,336	0,033	3,37			61,09	61,11	8,63
	0,994	46,858	46,858	1	4,686	0,080	4,77			98,87		
2	0,986	46,452	46,452	1	4,645	0,080	4,73	4,74	0,02	84,83		
	0,989	46,604	46,604	1	4,660	0,080	4,74			112,91	98,87	14,04

➢ **MP-KLI**

Waktu (Jam)	Absorbansi	Konsentrasi (µg/ml)	1 ml (µg)	Faktor DIlusi	100 ml (mg)	Faktor Koreksi	CUR release (mg)	Rata-Rata (mg)	SD	Pelepasan (%)	Rata-rata (%)	SD
0,5	0,184	5,746	5,746	1	0,575	0,000	0,575	0,557	0,021	0,28	0,33	0,05
	0,181	5,610	5,610	1	0,561	0,000	0,561			0,33		
	0,176	5,339	5,339	1	0,534	0,000	0,534			0,38		
1	0,229	8,048	8,048	1	0,805	0,008	0,813	0,827	0,014	0,93	1,08	0,15
	0,232	8,184	8,184	1	0,818	0,008	0,827			1,23		
	0,235	8,319	8,319	1	0,832	0,008	0,840			1,08		
2	0,331	13,197	13,197	1	1,320	0,021	1,341	1,408	0,067	4,32	4,32	0,61
	0,344	13,863	13,863	1	1,386	0,022	1,408			3,71		
	0,357	14,528	14,528	1	1,453	0,023	1,476			4,93		
3	0,410	17,190	17,190	1	1,719	0,038	1,757	1,825	0,068	6,37	7,43	1,06
	0,423	17,856	17,856	1	1,786	0,040	1,825			7,43		
	0,436	18,521	18,521	1	1,852	0,041	1,894			8,49		
4	0,469	20,185	20,185	1	2,019	0,059	2,077	2,216	0,138	12,29	14,32	2,03
	0,495	21,542	21,542	1	2,154	0,061	2,216			14,32		
	0,522	22,899	22,899	1	2,290	0,064	2,354			16,35		
5	0,549	24,255	24,255	1	2,426	0,083	2,508	2,648	0,140	25,43	25,43	3,61
	0,575	25,612	25,612	1	2,561	0,087	2,648			21,82		
	0,602	26,969	26,969	1	2,697	0,091	2,788			29,04		
6	0,629	28,326	28,326	1	2,833	0,111	2,944	3,085	0,141	45,03	39,43	5,60
	0,656	29,682	29,682	1	2,968	0,117	3,085			33,83		

	0,682	31,039	31,039	1	3,104	0,122	3,226			39,43		
	0,709	32,396	32,396	1	3,240	0,144	3,383			49,53		
7	0,736	33,752	33,752	1	3,375	0,150	3,526	3,526	0,143	56,56	49,53	7,03
	0,763	35,109	35,109	1	3,511	0,157	3,668			42,5		
	0,789	36,466	36,466	1	3,647	0,180	3,827			61,05		
8	0,816	37,822	37,822	1	3,782	0,188	3,971	3,971	0,144	45,78	53,43	7,63
	0,843	39,179	39,179	1	3,918	0,197	4,114			53,46		
	0,869	40,536	40,536	1	4,054	0,221	4,274			62,75		
12	0,896	41,892	41,892	1	4,189	0,230	4,419	4,419	0,145	83,51	73,13	10,38
	0,923	43,249	43,249	1	4,325	0,240	4,565			73,13		
	0,950	44,606	44,606	1	4,461	0,225	4,685			76,08		
24	0,976	45,963	45,963	1	4,596	0,234	4,831	4,831	0,145	89,84	89,84	13,76
	1,003	47,319	47,319	1	4,732	0,244	4,976			103,6		

Lampiran 5. Analisis Data dan Statistik

Lampiran 5.1 Analisis Statistik Ukuran Partikel

Tests of Normality

Formula		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Ukuran Partikel	F1	,292	3	.	,923	3	,463
	F2	,175	3	.	1,000	3	1,000
	F3	,175	3	.	1,000	3	1,000
	F4	,175	3	.	1,000	3	1,000
	F5	,175	3	.	1,000	3	1,000
	F6	,175	3	.	1,000	3	1,000

a. Lilliefors Significance Correction

One-way ANOVA

Ukuran Partikel

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	48,623	5	9,725	186,691	,000
Within Groups	,625	12	,052		
Total	49,248	17			

Multiple Comparisons

Dependent Variable: Ukuran Partikel

	(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval Lower Bound	95% Confidence Interval Upper Bound
Tukey HSD	F1	F2	-,55333	,18635	,095	-1,1793	,0726
		F3	-1,00333*	,18635	,002	-1,6293	-,3774
		F4	-2,44333*	,18635	,000	-3,0693	-1,8174
		F5	-3,35333*	,18635	,000	-3,9793	-2,7274
		F6	-4,66333*	,18635	,000	-5,2893	-4,0374
	F2	F1	,55333	,18635	,095	-,0726	1,1793
		F3	-,45000	,18635	,225	-1,0759	,1759
		F4	-1,89000*	,18635	,000	-2,5159	-1,2641
		F5	-2,80000*	,18635	,000	-3,4259	-2,1741

		F6	-4,11000*	,18635	,000	-4,7359	-3,4841
	F3	F1	1,00333*	,18635	,002	,3774	1,6293
		F2	,45000	,18635	,225	-,1759	1,0759
		F4	-1,44000*	,18635	,000	-2,0659	-,8141
		F5	-2,35000*	,18635	,000	-2,9759	-1,7241
		F6	-3,66000*	,18635	,000	-4,2859	-3,0341
	F4	F1	2,44333*	,18635	,000	1,8174	3,0693
		F2	1,89000*	,18635	,000	1,2641	2,5159
		F3	1,44000*	,18635	,000	,8141	2,0659
		F5	-,91000*	,18635	,004	-1,5359	-,2841
		F6	-2,22000*	,18635	,000	-2,8459	-1,5941
	F5	F1	3,35333*	,18635	,000	2,7274	3,9793
		F2	2,80000*	,18635	,000	2,1741	3,4259
		F3	2,35000*	,18635	,000	1,7241	2,9759
		F4	,91000*	,18635	,004	,2841	1,5359
		F6	-1,31000*	,18635	,000	-1,9359	-,6841
	F6	F1	4,66333*	,18635	,000	4,0374	5,2893
		F2	4,11000*	,18635	,000	3,4841	4,7359
		F3	3,66000*	,18635	,000	3,0341	4,2859
		F4	2,22000*	,18635	,000	1,5941	2,8459
		F5	1,31000*	,18635	,000	,6841	1,9359

Lampiran 5.2 Analisis Statistik Efisiensi Penjerapan

Tests of Normality

Efisiensi Penjerapan		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
Efisiensi Penjerapan	F1	,175	3	.	1,000	3	1,000
	F2	,175	3	.	1,000	3	1,000
	F3	,175	3	.	1,000	3	1,000
	F4	,175	3	.	1,000	3	1,000
	F5	,175	3	.	1,000	3	1,000
	F6	,175	3	.	1,000	3	1,000

a. Lilliefors Significance Correction

One-way ANOVA

Efisiensi Penjerapan

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	2994,642	5	598,928	55,290	,000
Within Groups	129,990	12	10,832		
Total	3124,631	17			

Multiple Comparisons

Dependent Variable: Efisiensi Penjerapan

	(I) Formula	(J) Formula	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval Lower Bound	95% Confidence Interval Upper Bound
Tukey HSD	F1	F2	-9,98000*	2,68731	,028	-19,0065	-,9535
		F3	-17,09000*	2,68731	,000	-26,1165	-8,0635
		F4	-31,64000*	2,68731	,000	-40,6665	-22,6135
		F5	-32,75000*	2,68731	,000	-41,7765	-23,7235
		F6	-34,01000*	2,68731	,000	-43,0365	-24,9835
	F2	F1	9,98000*	2,68731	,028	,9535	19,0065
		F3	-7,11000	2,68731	,159	-16,1365	1,9165
		F4	-21,66000*	2,68731	,000	-30,6865	-12,6335
		F5	-22,77000*	2,68731	,000	-31,7965	-13,7435
		F6	-24,03000*	2,68731	,000	-33,0565	-15,0035
	F3	F1	17,09000*	2,68731	,000	8,0635	26,1165
		F2	7,11000	2,68731	,159	-1,9165	16,1365
		F4	-14,55000*	2,68731	,002	-23,5765	-5,5235
		F5	-15,66000*	2,68731	,001	-24,6865	-6,6335
		F6	-16,92000*	2,68731	,000	-25,9465	-7,8935
	F4	F1	31,64000*	2,68731	,000	22,6135	40,6665
		F2	21,66000*	2,68731	,000	12,6335	30,6865
		F3	14,55000*	2,68731	,002	5,5235	23,5765
		F5	-1,11000	2,68731	,998	-10,1365	7,9165
		F6	-2,37000	2,68731	,944	-11,3965	6,6565
	F5	F1	32,75000*	2,68731	,000	23,7235	41,7765
		F2	22,77000*	2,68731	,000	13,7435	31,7965

		F3	15,66000*	2,68731	,001	6,6335	24,6865
		F4	1,11000	2,68731	,998	-7,9165	10,1365
		F6	-1,26000	2,68731	,996	-10,2865	7,7665
	F6	F1	34,01000*	2,68731	,000	24,9835	43,0365
		F2	24,03000*	2,68731	,000	15,0035	33,0565
		F3	16,92000*	2,68731	,000	7,8935	25,9465
		F4	2,37000	2,68731	,944	-6,6565	11,3965
		F5	1,26000	2,68731	,996	-7,7665	10,2865

*. The mean difference is significant at the 0.05 level.

Lampiran 5.3 Analisis Statistik *Drug Loading*

Tests of Normality

		Kolmogorov-Smirnov[a]			Shapiro-Wilk		
	Formula	Statistic	df	Sig.	Statistic	df	Sig.
Drug Loading	F1	,175	3	.	1,000	3	1,000
	F2	,175	3	.	1,000	3	1,000
	F3	,175	3	.	1,000	3	1,000
	F4	,175	3	.	1,000	3	1,000
	F5	,175	3	.	1,000	3	1,000
	F6	,175	3	.	1,000	3	1,000

a. Lilliefors Significance Correction

One-way ANOVA

Drug Loading

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	221,326	5	44,265	19,292	,000
Within Groups	27,534	12	2,295		
Total	248,860	17			

Multiple Comparisons

Dependent Variable: Drug Loading

(I)	(J)	Mean	Std.	Sig.	95% Confidence Interval

	Formula	Formula	Difference (I-J)	Error		Lower Bound	Upper Bound
Tukey HSD	F1	F2	5,09000*	1,23680	,014	,9357	9,2443
		F3	7,08000*	1,23680	,001	2,9257	11,2343
		F4	6,34000*	1,23680	,003	2,1857	10,4943
		F5	8,90000*	1,23680	,000	4,7457	13,0543
		F6	11,34000*	1,23680	,000	7,1857	15,4943
	F2	F1	-5,09000*	1,23680	,014	-9,2443	-,9357
		F3	1,99000	1,23680	,608	-2,1643	6,1443
		F4	1,25000	1,23680	,906	-2,9043	5,4043
		F5	3,81000	1,23680	,079	-,3443	7,9643
		F6	6,25000*	1,23680	,003	2,0957	10,4043
	F3	F1	-7,08000*	1,23680	,001	-11,2343	-2,9257
		F2	-1,99000	1,23680	,608	-6,1443	2,1643
		F4	-,74000	1,23680	,989	-4,8943	3,4143
		F5	1,82000	1,23680	,687	-2,3343	5,9743
		F6	4,26000*	1,23680	,043	,1057	8,4143
	F4	F1	-6,34000*	1,23680	,003	-10,4943	-2,1857
		F2	-1,25000	1,23680	,906	-5,4043	2,9043
		F3	,74000	1,23680	,989	-3,4143	4,8943
		F5	2,56000	1,23680	,362	-1,5943	6,7143
		F6	5,00000*	1,23680	,016	,8457	9,1543
	F5	F1	-8,90000*	1,23680	,000	-13,0543	-4,7457
		F2	-3,81000	1,23680	,079	-7,9643	,3443
		F3	-1,82000	1,23680	,687	-5,9743	2,3343
		F4	-2,56000	1,23680	,362	-6,7143	1,5943
		F6	2,44000	1,23680	,409	-1,7143	6,5943
	F6	F1	-11,34000*	1,23680	,000	-15,4943	-7,1857
		F2	-6,25000*	1,23680	,003	-10,4043	-2,0957
		F3	-4,26000*	1,23680	,043	-8,4143	-,1057
		F4	-5,00000*	1,23680	,016	-9,1543	-,8457
		F5	-2,44000	1,23680	,409	-6,5943	1,7143

*. The mean difference is significant at the 0.05 level.

Lampiran 6.Hasil Uji Kinetika Pelepasan Obat menggunakan Microsoft Excel (DD Solver)

- **Hixson-Crowell MP-KLI pada Media TSB kultur *S. aureus***

Time (h)	No.1 F(%)	Mean	SD	RSD(%)
0,5	0,33	0,33		
1	1,08	1,08		
2	4,32	4,32		
3	7,43	7,43		
4	14,32	14,32		
5	25,43	25,43		
6	39,43	39,43		
7	49,53	49,53		
8	53,46	53,46		
12	73,13	73,13		
24	89,84	89,84		

Best-fit Values				
Parameter	No.1	Mean	SD	RSD(%)
kH	16,249	16,249		

Secondary Parameter				
Parameter	No.1	Mean	SD	RSD(%)
T25	2,367	2,367		
T50	9,468	9,468		
T75	21,303	21,303		
T80	24,238	24,238		
T90	30,677	30,677		

Goodness of Fit	
Parameter	No.1
N_observed	11
DF	10
R_obs-pre	0,9632
Rsqr	0,7832
Rsqr_adj	0,7832
MSE	206,8821
MSE_root	14,3834
Weighting	1
SS	2068,8207
WSS	2068,8207
AIC	85,9821
MSC	1,3468

Lampiran 7. Dokumentasi Penelitian